MedTrace Logo

Parasitic Clearance and Recurrence Rates Among Patients With Vivax Malaria

NCT01784315 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2013-11-25

No results posted yet for this study

Summary

This research is intended to study the efficacy of CQ alone for P.vivax infection and also to study the recurrence rate among patients with P.vivax on standard dose of CQ and PQ. For this study, PQ will be withheld for 28 days so as to study the efficacy of CQ alone since masking effect over one another was found when CQ is given with PQ. So the investigators are not sure whether the recurrence is due to resistance to CQ or CQ concentration in blood is below therapeutic level or it is due to PQ is in inadequate dose. From this study the investigators will get findings like may be CQ is still working for P.vivax or no longer working for P.vivax due to resistance developed by P.vivax parasites. So for P.vivax which is not responding to CQ therapy, the investigators will go for second line treatment with ACT in a similar fashion as it is given for P. falciparum infection in Bhutan. And if the investigators find CQ is still working for P.vivax infection, the next level of study will be to compare higher dose of PQ with standard dose of PQ ( as practiced now) in lieu of bringing down the relapse rates in P. vivax infection.

Conditions

  • Parasitemia

Interventions

DRUG

Artemisinin combination therapies (ACT)will be used for Chloroquine resistant P.vivax

4 tablets of ACT on 0,8,24,36,48 and 60 hours will be given for Chloroquine resistant P.vivax infection.

DRUG

Chloroquine and Primaquine

Chloroquine:10mg/kg for day1,2 and 5mg/kg for day 3 Primaquine: 0.25mg/kg daily for 14 days.

Sponsors & Collaborators

  • Asia Pacific Malaria Elimination Network

    collaborator UNKNOWN

  • Menzies School of Health Research

    collaborator OTHER

  • Ministry of Health, Bhutan

    lead OTHER_GOV

Principal Investigators

  • Dr.Yeshey Dorjey · Ministry of Health, Bhutan

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • Bhutan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01784315 on ClinicalTrials.gov